Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Oragenics, Inc.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Agilis Biotherapeutics has entered into a deal with synthetic biology firm Intrexon to develop DNA-based therapeutics for the rare genetic disease, Friedreich's ataxia.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced October through November 2013.
A new life sciences hedge fund operated by two former associates of activist investor Carl Icahn is challenging Otsuka’s takeover of cancer drug developer Astex. Also, Johnson & Johnson’s London Innovation Center announced four alliances, Celgene took another option on one of its investments and Takeda teamed up with New York research institutions to form a new discovery institute.
- OTC, Consumer